title: Evidence that the soluble interleukin 2 receptor level may determine the optimal time for cystoscopically-directed biopsy in pancreaticoduodenal allograft recipients.
abstract: In 18 consecutive pancreaticoduodenal allograft recipients (15 combined kidney/pancreas and 3 pancreas only after a prior successful kidney transplantation) operated on between December 1987 and February 1989, we studied the soluble interleukin 2 receptor (SIL-2R) level over time. All pancreaticoduodenal allografts were transplanted with exocrine drainage via a duodenocystostomy that allowed for cystoscopically directed needle biopsies of the pancreas. Of these 18 recipients, at 6 weeks after transplantation, 6 had had no rejection episodes or cytomegalovirus disease (control group), an acute allograft rejection had developed in 7, CMV disease developed in 4, and both rejection and CMV disease developed in 1 by 12 days after transplantation. SIL-2R level increased in all patients during immunosuppressive induction therapy (preoperative mean +/- SE, 1637 +/- 284 U/mL; maximum, 4367 +/- 687 U/mL). After induction therapy, the mean was 2768 +/- 432 U/mL. In all 6 recipients in the control group, SIL-2R level continued to decrease. However, SIL-2R level was significantly higher compared with controls, in those who had CMV disease (levels were increased at a mean of 7 days before diagnosis of CMV disease) and in those who had acute rejection episodes (levels were increased a mean of 7 days before the clinical diagnosis of rejection). Factors that did not cause an increase in SIL-2R level included acute pancreatitis, wound infection, operative procedures, and CsA nephrotoxicity. SIL-2R level can be useful for monitoring pancreaticoduodenal allograft recipients. Increases predict impending rejection or CMV disease, prior to the onset of organ dysfunction. When SIL-2R level increases, we recommend cultures of blood and urine to exclude CMV and pancreaticoduodenal allograft biopsy to confirm early rejection prior to the initiation of potentially dangerous antirejection therapy.
authors.affiliation: Section of Transplantation Surgery, Mayo Clinic, Rochester, Minnesota 55905.
authors.forename: J D
authors.initials: JD
authors.lastname: Perkins
authors.forename: S R
authors.initials: SR
authors.lastname: Munn
authors.forename: D
authors.initials: D
authors.lastname: Barr
authors.forename: D C
authors.initials: DC
authors.lastname: Ferguson
authors.forename: H A
authors.initials: HA
authors.lastname: Carpenter
mesh_terms: D001706:Biopsy; D003586:Cytomegalovirus Infections / Q000150:complications / Q000276:immunology; D004386:Duodenum / Q000637:transplantation; D006084:Graft Rejection; D006801:Humans; D016035:Pancreas Transplantation / Q000276:immunology*; D010182:Pancreatic Diseases / Q000175:diagnosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D013997:Time Factors
chemical_list: D015375:Receptors, Interleukin-2